证券代码：000963 证券简称：华东医药 公告编号：2025-113 华东医药股份有限公司 关于全资子公司收到一审民事判决书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼（仲裁）阶段：一审判决 2、上市公司所处的当事人地位：原告 驳回杭州中美华东制药有限公司的全部诉讼请求。 3、涉案的金额：111,386,405元（较首次披露暂计金额增加 10,600元） 4、对上市公司损益产生的影响：本次诉讼案件尚处于一审判决 阶段，对公司本期利润及期后利润不构成重大影响，公司将依法向中 华人民共和国最高人民法院提起上诉，并根据上诉进展情况及时履行 信息披露义务。 华东医药股份有限公司（以下简称"公司"或"本公司"）全资 子公司杭州中美华东制药有限公司（以下简称"中美华东"）于近日 收到浙江省高级人民法院送达的《民事判决书》（(2023) 浙知民初3 号）。现将有关事项公告如下： 一、本次诉讼的基本情况 因侵害发明专利权纠纷，中美华东将青海珠峰冬虫夏草原料有限 公司、青海珠峰冬虫夏草药业有限公司、杭州华东武林大药房有限公 1 / 4 ...

Core Viewpoint - CITIC Securities report indicates that Huadong Medicine's operations remain stable in the first three quarters of 2025, with performance meeting previous expectations, maintaining a "Buy" rating [1] Segment Summaries Pharmaceutical Industry - The pharmaceutical manufacturing sector shows strong profit performance, with innovative momentum gradually being released [1] Pharmaceutical Commerce - The pharmaceutical commerce segment has returned to a growth trajectory, demonstrating resilience in response to industry changes [1] Aesthetic Medicine - Domestic and international aesthetic medicine sectors are undergoing adjustments due to external environmental impacts, while pipeline layout continues to advance [1] Microbial Products - The microbial products segment maintains rapid growth and is actively expanding into overseas markets [1] Future Outlook - The progress of innovation transformation is expected to be realized, with attention on subsequent data disclosures and potential external collaborations [1] - The aesthetic medicine pipeline is entering a harvest phase, which is anticipated to bring profit elasticity [1] - The microbial products segment has multiple catalysts, strengthening overseas expansion [1]

Core Insights - The pharmaceutical distribution industry is a crucial component of the national healthcare system and health industry, significantly impacting public health and safety [1][7] - The industry is experiencing growth due to the implementation of the "two-invoice system" reform and increasing public awareness of healthcare [1][7] Industry Overview - The pharmaceutical distribution market in China is projected to reach a sales volume of 29,470 billion yuan in 2024, with wholesale sales accounting for 22,970 billion yuan (77.94%) and retail sales for 6,500 billion yuan (22.06%) [1][7] - The regional distribution of sales shows that East China accounts for 36.3%, Central South 27.0%, North China 15.2%, Southwest 13.4%, Northeast 4.3%, and Northwest 3.8%, with the top three regions contributing to 78.5% of total sales [9][10] Sales Structure - The sales composition indicates that Western medicine accounts for 70.8% of total sales, followed by traditional Chinese medicine at 14.6%, medical devices at 7.7%, and other categories [9][10] Current State of the Industry - As of the end of 2024, there are 705,400 licensed pharmaceutical businesses in China, including 15,100 wholesale companies and 66,070 retail chain enterprises [3][5] - The total number of retail pharmacies has increased to 683,700, with a notable rise in single retail pharmacies [3][5] Financial Performance - In 2024, the main business income of reported pharmaceutical distribution enterprises reached 22,431 billion yuan, reflecting a 0.8% increase from 2023, while the profit totaled 468 billion yuan with an average gross margin of 7.2% [5][6] Industry Chain - The pharmaceutical distribution industry serves as a critical link in the pharmaceutical supply chain, connecting manufacturers with end-users, including hospitals and pharmacies [11][12] Competitive Landscape - Major players in the pharmaceutical distribution sector include East China Pharmaceutical, Shanghai Pharmaceutical, China National Pharmaceutical Group, and others, with significant revenue contributions from these companies [14][15] Future Development Directions - The industry aims to enhance operational efficiency and inventory management to ensure a stable supply of pharmaceuticals while minimizing financial risks [18][19]

Group 1 - The 2024-2025 Annual Marketing Conference and the 23rd Outstanding Brand Marketing Annual Meeting will be held in Beijing, focusing on the collision between brand economy and traffic economy, aiming to promote brand competition from "traffic competition" to "value cultivation" [1] - On December 10, a total of 1.41 million shares from 8 companies will be unlocked, with a total market value of 2.388 billion yuan, including significant unlocks from Nanshan Zhishang, Xingtong Co., and Yunding Technology [1] - The unlocked shares include over 10 million shares from three companies, with Nanshan Zhishang leading at 71.4286 million shares, followed by Xingtong Co. at 41.4916 million shares, and Yunding Technology at 10.0526 million shares [1] Group 2 - Nine companies disclosed stock repurchase progress on December 10, with five companies announcing new repurchase plans, one plan approved by shareholders, and three plans completed [2] - Among the new repurchase plans, four companies announced amounts exceeding 10 million yuan, with Huitai Medical, Songcheng Performance, and Jinggu Co. having the highest proposed repurchase amounts of 250 million yuan, 200 million yuan, and 60 million yuan respectively [2] - Huadong Medicine has the highest repurchase amount approved by shareholders, proposing to repurchase up to 6.494 million yuan [2]

Meeting Overview - The second extraordinary general meeting of shareholders for East China Pharmaceutical Co., Ltd. is scheduled for December 9, 2025, at 14:00, located at the company's new building in Hangzhou, Zhejiang Province [3][4] - The meeting will utilize a combination of on-site and online voting methods, convened by the board of directors and presided over by the chairman, Lü Liang [4] Attendance Details - A total of 526 shareholders attended the meeting, representing 1,074,532,240 shares, which accounts for 61.2611% of the total voting shares [5] - Among them, 524 small shareholders participated, representing 55,594,083 shares, or 3.1695% of the total voting shares [5] Proposal Voting Results - The proposal to repurchase and cancel part of the restricted stock was approved with 1,074,435,740 votes in favor, representing 99.9910% of the valid votes [7] - The proposal to expand the business scope, change registered capital, and amend the Articles of Association was also approved with 1,074,460,440 votes in favor, representing 99.9933% of the valid votes [8] Legal Opinion - The legal opinion provided by Zhejiang Tian Ce Law Firm confirms that the meeting's convening and voting procedures comply with relevant laws and regulations, and the voting results are valid [9] Stock Repurchase Announcement - The company plans to repurchase and cancel a total of 284,200 shares of restricted stock at a price of 22.85 yuan per share, funded by the company's own resources [12] - Following the repurchase, the total number of shares will decrease from 1,754,021,048 to 1,753,736,848, and the registered capital will reduce from 1,754,021,048 yuan to 1,753,736,848 yuan [13]

Meeting Information - The meeting was held on December 9, 2025, at 14:00 in Hangzhou, Zhejiang Province, at the new building of East China Pharmaceutical Co., Ltd. [3] - The meeting was conducted through a combination of on-site and online voting [4] Attendance - A total of 526 shareholders attended the meeting, representing 1,074,532,240 shares, which is 61.2611% of the total voting shares [5] - Among them, 524 minority shareholders participated, representing 55,594,083 shares, or 3.1695% of the total voting shares [6] Proposal Voting Results - The proposal to repurchase and cancel part of the restricted stock was approved with 1,074,435,740 shares in favor, accounting for 99.9910% of the valid votes [7] - Minority shareholders voted 55,497,583 shares in favor, representing 99.8264% of the valid votes [9] - The proposal to expand the business scope and amend the registered capital was also approved with 1,074,460,440 shares in favor, which is 99.9933% of the valid votes [10] - Minority shareholders voted 55,522,283 shares in favor, representing 99.8708% of the valid votes [11] Legal Opinion - The legal opinion from Zhejiang Tianche Law Firm confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations [12] Share Capital Changes - Following the repurchase, the total number of shares will decrease from 1,754,021,048 to 1,753,736,848 shares, and the registered capital will reduce from 1,754,021,048 yuan to 1,753,736,848 yuan [15]

证券代码：000963 证券简称：华东医药 公告编号：2025-112 华东医药股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、通知债权人的原因 华东医药股份有限公司（以下简称"公司"） 于2025年11月20日 召开的第十一届董事会第五次会议审议通过了《关于回购注销部分限 制性股票的议案》，并于2025年12月09日召开2025年第二次临时股东 会，审议通过了《关于回购注销部分限制性股票的议案》，对首次授 予激励对象中6名因离职不再具备激励资格的激励对象、16名因第三 个解除限售期个人层面绩效考核结果为不合格的激励对象、3名因第 三个解除限售期个人层面绩效考核结果为合格的激励对象及预留授 予激励对象中1名因离职不再具备激励资格的激励对象、2名因第二个 解除限售期个人层面绩效考核结果为不合格的激励对象，对应的已获 授但尚未解除限售的限制性股票合计28.42万股进行回购注销。回购 价格为22.85元/股，回购资金来源为公司自有资金。 债权申报所需材料： 公司债权人可持证明债权债务关系存 ...

法律意见书 浙江天册律师事务所 关于 华东医药股份有限公司 2025 年第二次临时股东会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于华东医药股份有限公司 2025 年第二次临时股东会的 法律意见书 编号：TCYJS2025H2096 号 致：华东医药股份有限公司 （一）经本所律师核查，公司本次股东会由董事会提议并召集，召开本次股东 会的通知已于 2025 年 11 月 22 日在指定媒体及深圳证券交易所网站上公告。 （二）本次股东会采取现场投票与网络投票相结合的方式。 1 法律意见书 根据本次股东会的会议通知，本次股东会现场会议召开的时间为 2025 年 12 月 9 日下午 14:00；召开地点为浙江省杭州市拱墅区莫干山路 858 号华东医药股份有 限公司新大楼 3 楼三潭印月会议室。经本所律师的审查，本次股东会现场会议召 开的实际时间、地点与本次股东会的会议通知中所告知的时间、地点一致。 浙江天册律师事务所（以下简称"本所"）接受华东医药股份有限公司（以下 简 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无否决提案情形，也不涉及变更以往股东会已通 过决议的情形； 2、本次股东会对中小股东单独计票。中小股东是指：除公司董 事、高级管理人员以及单独或合计持有公司5%以上股份的股东以外 的其他股东。 一、会议召开情况 1、现场会议召开时间：2025年12月09日（星期二）下午14:00 证券代码：000963 证券简称：华东医药 公告编号：2025-111 华东医药股份有限公司 2025年第二次临时股东会决议公告 其中：通过现场投票的股东11人，代表股份1,020,331,667股，占 公司有表决权股份总数的58.1710%。 通过网络投票的股东515人，代表股份54,200,573股，占公司有表 决权股份总数的3.0901%。 2、中小股东出席的总体情况： 2、召开地点：浙江省杭州市拱墅区莫干山路858号华东医药股份 有限公司新大楼3楼三潭印月会议室。 3、召开方式：现场投票与网络投票相结合的表决方式 4、召集人：公司董事会 5、主持人：公司董事长 吕梁 6、本次会议召集、召开与表决程序符合 ...

Core Viewpoint - Huadong Medicine (000963) has seen a slight increase in stock price and market capitalization, with recent announcements regarding the inclusion of its products in national medical insurance and commercial health insurance directories, which may benefit future market promotion but will not significantly impact recent performance [1]. Group 1: Stock Performance - As of December 8, 2025, Huadong Medicine's stock closed at 42.52 yuan, up 0.93% from the previous trading day [1]. - The stock opened at 42.58 yuan, reached a high of 43.07 yuan, and a low of 42.09 yuan, with a trading volume of 2.94 billion yuan and a turnover rate of 0.39% [1]. Group 2: Product Inclusion in Directories - On December 7, 2025, the National Healthcare Security Administration and other departments released a new version of the drug directory and commercial health insurance innovative drug directory [1]. - Huadong Medicine's subsidiary, Sino-American Huadong, has had its Ustinumab injection included in the regular directory management, with payment scope remaining unchanged [1]. - The company's cooperative products, Senapali capsules and Pentanedioic acid linaclotide capsules, have been included in the negotiated drug directory, while Zevokiorun injection has been added to the commercial insurance innovative drug directory [1]. - The new directory will take effect on January 1, 2026, and the inclusion of these products is expected to facilitate future market promotion, although it will not have a significant impact on the company's recent performance [1].